Table 1. Demographic characteristics of study participants

	Pre-Covid Phase	Covid Phase	P value
	N=2577	N=2290	
Age, in years			0.99
18-24	3 (0.1%)	2 (0.1%)	
25-44	236 (9.2%)	211 (9.2%)	
45-64	1135 (44.0%)	1020 (44.5%)	
65-84	1095 (42.5%)	959 (41.9%)	
85+	108 (4.2%)	98 (4.3%)	
Cancer Stage			<0.001
1	1602 (62.2%)	1621 (70.8%)	
2	578 (22.4%)	349 (15.2%)	
3	266 (10.3%)	203 (8.9%)	
4	131 (5.1%)	117 (5.1%)	
Had Radiation Treatment	1145 (44.4%)	1435 (62.7%)	<0.001
Had Systemic Treatment	1151 (44.7%)	1589 (69.4%)	<0.001
Had Surgery	1226 (47.6%)	1013 (44.2%)	0.020
Average time to treatment (days)	94	48	<0.001
Average time to surgery (days)	89	69	<0.001

Table 3. Neoadjuvant chemotherapy, neoadjuvant endocrine therapy, radiotherapy and immediate breast reconstruction in surgical patients with breast cancer.

	Stage 1		Stage 2		Stage 3		Stage 4	
	Pre-covid	Covid	Pre-covid	Covid	Pre-covid	Covid	Pre-covid	Covid
	N=767	N=740	N=304	N=156	N=127	N=103	N=28	N=14
Neoadjuvant chemotherapy	33 (4.3%)	61 (8.2%)	55 (18.1%)	48 (30.8%)	49 (38.6%)	55 (53.4%)	11 (39.3%)	5 (35.7%)
Neoadjuvant endocrine therapy	25 (3.3%)	54 (7.3%)	55 (18.1%)	48 (30.8%)	46 (36.2%)	54 (52.4%)	9 (32.1%)	4 (28.6%)
Radiation therapy	360 (46.9%)	515 (69.6%)	130 (42.8%)	105 (67.3%)	81 (63.8%)	89 (86.4%)	15 (53.6%)	13 (92.9%)
Immediate breast reconstruction	76 (9.9%)	75 (10.1%)	30 (9.9%)	25 (16.0%)	17 (13.4%)	16 (15.6%)	2 (7.1%)	2 (14.3%)